Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LGVN

Longeveron Inc

May 07 • 04:00PM ET

1.68

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-5.83	Insider Own	69.95%	Shs Outstand	1.03M	Perf Week	-1.75%
Market Cap	5.46M	Forward P/E	-	EPS next Y	-15.35	Insider Trans	16.55%	Shs Float	0.98M	Perf Month	-21.86%
Income	-22.21M	PEG	-	EPS next Q	-2.00	Inst Own	7.70%	Short Float	9.29%	Perf Quarter	-68.30%
Sales	0.71M	P/S	7.69	EPS this Y	42.68%	Inst Trans	23.22%	Short Ratio	0.04	Perf Half Y	-91.43%
Book/sh	2.72	P/B	0.62	EPS next Y	-162.49%	ROA	-107.90%	Short Interest	0.09M	Perf Year	-94.56%
Cash/sh	1.65	P/C	1.02	EPS next 5Y	-	ROE	-156.05%	52W Range	1.60 - 44.00	Perf YTD	-87.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-25.24%	ROI	-267.96%	52W High	-96.18%	Beta	0.47
Dividend TTM	-	Quick Ratio	1.50	Sales past 5Y	7.76%	Gross Margin	-102.12%	52W Low	5.00%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	1.50	EPS Y/Y TTM	-13.77%	Oper. Margin	-2966.01%	RSI (14)	36.52	Volatility	10.05% 18.35%
Employees	25	Debt/Eq	0.30	Sales Y/Y TTM	-41.98%	Profit Margin	-3132.72%	Recom	1.00	Target Price	14.05
Option/Short	No / Yes	LT Debt/Eq	0.21	EPS Q/Q	-1103.63%	Payout	-	Rel Volume	0.16	Prev Close	1.68
Sales Surprise	-70.00%	EPS Surprise	-17.19%	Sales Q/Q	-47.93%	Earnings	May 14 AMC	Avg Volume	2.15M	Price	1.68
SMA20	-15.56%	SMA50	-49.24%	SMA200	-88.93%	Trades		Volume	348,929	Change	0.00%

May-02-24 08:03AM	Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-25-24 04:05PM	Longeveron to Present at the Planet MicroCap Showcase (GlobeNewswire)
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-18-24 04:05PM	Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering (GlobeNewswire)
08:00AM	Loading…
Apr-17-24 08:00AM	Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds (GlobeNewswire) -40.79%
Apr-16-24 01:08PM	Hedge Fund and Insider Trading News: Ken Griffin, Per Johansson, David Tepper, Michael Platt, Third Point LLC, Millennium Management, Bridgewater Associates, Paloma Partners, Longeveron Inc (LGVN), MongoDB, Inc. (MDB) and More (Insider Monkey) +20.48%
Apr-15-24 08:30AM	Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC) (GlobeNewswire) +73.37%
08:24AM	Why Is Longeveron (LGVN) Stock Up 48% Today? (InvestorPlace)
Apr-11-24 05:17PM	Longeveron Announces Closing of $5.2 Million Public Offering (GlobeNewswire) -10.22%
Apr-08-24 02:15PM	Longeveron Announces Pricing of $5.25 Million Public Offering (GlobeNewswire)
08:30AM	Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals (GlobeNewswire)
07:56AM	Why Is Longeveron (LGVN) Stock Up 82% Today? (InvestorPlace)
Mar-19-24 04:01PM	Longeveron Announces 1-for-10 Reverse Stock Split (GlobeNewswire)
Feb-28-24 10:05AM	With cash runways ending this year, Nicox and Longeveron trim staff and narrow focus (FierceBiotech.com) -5.95%
09:19AM	Loading…
09:19AM	Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:05PM	Longeveron Reports Year-End 2023 Results and Provides Corporate Update (GlobeNewswire) +7.19%
Feb-21-24 04:05PM	Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024 (GlobeNewswire)
Jan-29-24 08:00AM	Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B (GlobeNewswire) -16.07%
Dec-22-23 04:05PM	Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +7.20%
Dec-21-23 10:34AM	UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -22.84%
08:00AM	Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Dec-20-23 08:00AM	Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.92%
Nov-14-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa'el Hashad, CEO of Longeveron Inc. (GlobeNewswire)
Nov-11-23 09:00AM	Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
08:38AM	Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:30AM	Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire) -5.70%
Nov-03-23 08:00AM	Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 (GlobeNewswire)
Oct-24-23 08:30AM	Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B for the Treatment of Mild Alzheimer's (GlobeNewswire)
Oct-13-23 04:05PM	Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:00AM	Loading…
Oct-12-23 08:00AM	Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.24%
Oct-05-23 07:00AM	Longeveron Announces Positive Top-Line Results for Lomecel-B in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease (GlobeNewswire) -16.73%
Sep-12-23 09:00AM	Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market (News Direct)
Sep-11-23 08:00AM	Longeveron Issues Letter to Stockholders (GlobeNewswire)
Sep-07-23 08:30AM	IBN Coverage Initiated for Longeveron Inc. (GlobeNewswire)
08:00AM	Long-term Survival Data from Longeverons ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association (GlobeNewswire)
Sep-05-23 08:00AM	Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire)
Aug-29-23 08:00AM	Longeveron to Participate in the 149th Annual National Investment Banking Association Conference (GlobeNewswire)
Aug-22-23 08:00AM	Longeveron Rights Offering Subscription Period Begins (GlobeNewswire) +8.20%
Aug-16-23 09:13AM	Longeveron Rights Offering Declared Effective and Calendar Finalized (GlobeNewswire)
Aug-14-23 04:05PM	Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B on August 16, 2023 (GlobeNewswire) -7.03%
08:00AM	Longeveron Announces Pricing for Rights Offering and Expected Calendar (GlobeNewswire)
Aug-11-23 07:30AM	Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
07:24AM	LGVN Makes Progress in Treatment for Devastating Diseases (Zacks Small Cap Research)
07:00AM	Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B in Hypoplastic Left Heart Syndrome (GlobeNewswire)
Aug-08-23 09:25AM	Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions (News Direct)
07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Aug-07-23 08:00AM	Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Longeveron Appoints Lisa Locklear as Chief Financial Officer (GlobeNewswire)
Jul-11-23 08:00AM	Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer (GlobeNewswire)
Jul-10-23 08:00AM	Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors (GlobeNewswire)
Jul-07-23 09:00AM	HLHS Is A Rare And Serious Congenital Heart Disease With A 33% Neonatal Death Rate Could Longeverons Lomecel-B Improve Outcomes? (News Direct)
Jul-06-23 11:12AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.) -5.66%
Jun-27-23 06:07PM	Longeveron Files Registration Statement for Rights Offering (GlobeNewswire) -5.85%
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire)
May-12-23 08:32AM	LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates (InvestorPlace)
08:20AM	LGVN: Announces Results and Progress on a Devastating Disease (Zacks Small Cap Research)
08:00AM	Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-09-23 05:23PM	Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free (Benzinga) +26.58%
08:30AM	Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B for Hypoplastic Left Heart Syndrome (GlobeNewswire)
May-08-23 08:30AM	Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023 (GlobeNewswire)
Apr-19-23 08:59AM	Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B for Aging-Related Frailty in Japan (GlobeNewswire)
Mar-14-23 02:38PM	Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51% (Simply Wall St.)
Mar-10-23 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -11.49%
06:10AM	LGVN: Longeveron Continues Progress Toward Important Treatments (Zacks Small Cap Research)
Mar-07-23 04:18PM	Insiders Just Bought $1 Million of This Deep Value Tech Stock (InvestorPlace)
Mar-06-23 08:30AM	Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023 (GlobeNewswire)
Feb-28-23 08:30AM	Longeveron Appoints Wael Hashad as Chief Executive Officer (GlobeNewswire)
Jan-27-23 08:51AM	Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely? (Simply Wall St.)
Jan-19-23 08:35AM	LGVN: Longeveron Posts Positive Results for Life-Threatening Condition (Zacks Small Cap Research)
08:30AM	Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal (GlobeNewswire)
Jan-06-23 09:58AM	UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones (GlobeNewswire) +9.51%
08:30AM	Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones (GlobeNewswire)
Nov-29-22 04:30PM	Longeveron to Participate in Upcoming 2022 Investor Conferences (GlobeNewswire) -9.18%
Nov-16-22 05:32AM	Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
Nov-14-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
07:15AM	LGVN: Making Exciting Progress (Zacks Small Cap Research)
Nov-10-22 08:30AM	Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B for the Treatment of Alzheimers Disease (GlobeNewswire) +15.85%
Nov-07-22 09:06AM	Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Oct-05-22 02:34PM	Investing in Longeveron (NASDAQ:LGVN) a year ago would have delivered you a 13% gain (Simply Wall St.)
11:00AM	Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market (InvestorPlace)
08:30AM	Longeveron to Present at the Annual Dawson James Small Cap Growth Conference (GlobeNewswire)
Sep-15-22 08:30AM	Longeveron Names Jerome Bailey Vice President of Business Operations (GlobeNewswire)
Sep-06-22 08:30AM	Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-31-22 08:30AM	U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeverons Lomecel-B Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants (GlobeNewswire) -7.80%
07:30AM	EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants (Benzinga)
Aug-25-22 08:00AM	Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B Cell Therapy Through Levels of Vascular Biomarker (GlobeNewswire)
07:30AM	EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent (Benzinga)
Aug-20-22 08:45AM	We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate (Simply Wall St.)
Aug-12-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
07:36AM	LGVN: Quarterly Report Provides Good News (Zacks Small Cap Research)
Aug-08-22 08:30AM	Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022 (GlobeNewswire)
Jul-27-22 09:33AM	LGVN: Alzheimers Study Gains Traction as CEO Search Continues (Zacks Small Cap Research)
Jul-07-22 08:00AM	Longeveron Announces Abstract Accepted for Presentation at the Alzheimers Association International Conference (AAIC) (GlobeNewswire) +21.18%
Jun-26-22 10:22AM	What Type Of Shareholders Make Up Longeveron Inc.'s (NASDAQ:LGVN) Share Registry? (Simply Wall St.)
May-21-22 10:16AM	Multiple insiders bought Longeveron Inc. (NASDAQ:LGVN) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
May-13-22 08:00AM	Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +10.80%
07:12AM	LGVN: CEO Leaving but Progress Continues (Zacks Small Cap Research)
May-09-22 04:15PM	Longeveron Announces CEO Transition (GlobeNewswire)

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hare Joshua	Chief Scientific Officer	Apr 11 '24	Buy	2.35	42,553	100,000	633,280	Apr 12 07:00 PM
Soffer Rock	Director	Apr 11 '24	Buy	2.35	31,915	75,000	208,534	Apr 12 07:00 PM
Hashad Mohamed Wa'el Ahmed	Chief Executive Officer	Apr 11 '24	Buy	2.35	10,638	24,999	19,616	Apr 12 07:00 PM
Soffer Rock	Director	Apr 10 '24	Buy	2.35	106,383	250,000	176,619	Apr 12 07:00 PM
Hare Joshua	Chief Scientific Officer	Apr 10 '24	Buy	2.35	106,383	250,000	590,727	Apr 12 07:00 PM
Ross Cathy	Director	Jan 10 '24	Buy	1.31	5,000	6,544	10,000	Jan 11 06:00 PM
Baluch Khoso	Director	Dec 29 '23	Buy	1.43	8,322	11,915	15,000	Jan 02 06:00 PM
PFEFFER JEFFREY	Director	Dec 28 '23	Buy	1.35	10,000	13,500	15,000	Dec 29 05:00 PM
Baluch Khoso	Director	Dec 28 '23	Buy	1.40	1,678	2,342	6,678	Jan 02 06:00 PM
Hare Joshua	Chief Scientific Officer	Sep 21 '23	Option Exercise	3.00	5,000	15,000	7,828,263	Sep 22 07:00 PM
Lehr Paul T	General Counsel, Secretary	Sep 20 '23	Option Exercise	3.00	2,000	6,000	144,213	Sep 21 05:00 PM
Hare Joshua	Chief Scientific Officer	Sep 12 '23	Option Exercise	3.00	30,000	90,000	7,823,263	Sep 14 05:09 PM
Hashad Mohamed Wa'el Ahmed	Chief Executive Officer	Sep 12 '23	Option Exercise	3.00	10,000	30,000	47,566	Sep 13 05:00 PM
Soffer Rock	Director	Sep 08 '23	Option Exercise	3.00	30,000	90,000	702,351	Sep 12 05:00 PM
Clavijo James	CFO and Treasurer	Jun 29 '23	Sale	3.51	5,000	17,550	47,303	Jun 29 05:00 PM
Clavijo James	CFO and Treasurer	Jun 28 '23	Sale	3.43	10,000	34,300	52,303	Jun 29 05:00 PM
Clavijo James	CFO and Treasurer	Jun 27 '23	Sale	3.48	8,532	29,691	62,303	Jun 29 05:00 PM

Open in Screener

PCSA

Processa Pharmaceuticals Inc

May 07 • 04:00PM ET

2.48

Dollar change +0.13
Percentage change 5.53	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

PCSA Processa Pharmaceuticals Inc daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-8.88	Insider Own	19.97%	Shs Outstand	2.86M	Perf Week	13.76%
Market Cap	7.09M	Forward P/E	-	EPS next Y	-1.89	Insider Trans	12.40%	Shs Float	2.29M	Perf Month	-16.92%
Income	-11.12M	PEG	-	EPS next Q	-1.18	Inst Own	1.94%	Short Float	8.28%	Perf Quarter	4.20%
Sales	0.00M	P/S	-	EPS this Y	55.79%	Inst Trans	4.99%	Short Ratio	0.13	Perf Half Y	-64.37%
Book/sh	3.88	P/B	0.64	EPS next Y	50.52%	ROA	-154.40%	Short Interest	0.19M	Perf Year	-82.78%
Cash/sh	1.65	P/C	1.51	EPS next 5Y	15.00%	ROE	-178.52%	52W Range	1.40 - 18.00	Perf YTD	-62.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	9.70%	ROI	-219.96%	52W High	-86.22%	Beta	0.59
Dividend TTM	-	Quick Ratio	7.71	Sales past 5Y	0.00%	Gross Margin	-	52W Low	77.14%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	7.71	EPS Y/Y TTM	74.04%	Oper. Margin	0.00%	RSI (14)	58.84	Volatility	9.59% 15.50%
Employees	13	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	44.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	88.48%	Payout	-	Rel Volume	0.09	Prev Close	2.35
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.49M	Price	2.48
SMA20	28.35%	SMA50	13.86%	SMA200	-57.25%	Trades		Volume	127,386	Change	5.53%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-24	Initiated	H.C. Wainwright	Buy	$8

May-06-24 08:00AM	Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference (GlobeNewswire) +8.29%
Apr-30-24 08:00AM	Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research (GlobeNewswire)
Apr-11-24 08:00AM	Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial (GlobeNewswire)
Mar-28-24 08:15AM	Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire)
Mar-25-24 08:15AM	Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
08:15AM	Loading…
Feb-21-24 08:15AM	Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.47%
Feb-14-24 01:00PM	Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference (GlobeNewswire)
Feb-06-24 08:30AM	Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Feb-01-24 04:22PM	Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering (GlobeNewswire)
Jan-26-24 09:04AM	Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -28.04%
Jan-25-24 02:40PM	Why Is Processa Therapeutics (PCSA) Stock Up 90% Today? (InvestorPlace) +148.78%
08:30AM	Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses (GlobeNewswire)
Jan-19-24 07:45AM	Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer (GlobeNewswire) +10.84%
Jan-18-24 07:45AM	Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split (GlobeNewswire) -25.31%
Jan-02-24 05:06PM	Processa Pharmaceuticals to Present at the Biotech Showcase 2024 (GlobeNewswire) +5.71%
09:00AM	Loading…
Dec-19-23 09:00AM	Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine (GlobeNewswire) -21.36%
Dec-13-23 09:00AM	Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine (GlobeNewswire) -25.40%
Nov-30-23 08:15AM	Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference (GlobeNewswire) +20.53%
Nov-29-23 08:15AM	Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook (GlobeNewswire) +17.95%
Nov-13-23 01:40PM	Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson (GlobeNewswire) +20.68%
Nov-09-23 08:15AM	Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas (GlobeNewswire) -6.72%
Nov-01-23 08:15AM	Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders (GlobeNewswire)
Oct-13-23 01:08PM	Processa Pharmaceuticals to Present at the ThinkEquity Conference (GlobeNewswire) +45.41%
Sep-06-23 08:15AM	Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-17-23 08:05AM	Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:15PM	Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference (GlobeNewswire)
Aug-08-23 08:15AM	Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer (GlobeNewswire)
Jun-14-23 04:15PM	Next Generation Chemotherapy: Improved Treatment for More Patients (GlobeNewswire)
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire) -5.45%
08:05AM	Loading…
May-22-23 08:05AM	Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress (GlobeNewswire)
May-18-23 08:00AM	Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative (GlobeNewswire)
Apr-28-23 08:15AM	Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting (GlobeNewswire) +14.46%
Mar-30-23 04:01PM	Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results (GlobeNewswire) +5.63%
Mar-23-23 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST (GlobeNewswire)
Mar-17-23 08:30AM	Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine (GlobeNewswire) +10.64%
Mar-07-23 08:30AM	Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 08:30AM	Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies (GlobeNewswire)
Feb-15-23 08:30AM	Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Feb-10-23 08:00AM	Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Jan-04-23 08:30AM	Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023. (GlobeNewswire)
Dec-14-22 08:30AM	Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial (GlobeNewswire)
Nov-08-22 04:00PM	Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
08:30AM	PCS12852 Improves Gastric Emptying in Gastroparesis Patients (GlobeNewswire)
Nov-02-22 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST (GlobeNewswire) -6.38%
Nov-01-22 08:30AM	Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial (GlobeNewswire) +7.75%
Sep-15-22 08:30AM	Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs (GlobeNewswire)
Sep-07-22 08:30AM	Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022 (GlobeNewswire)
Aug-16-22 08:30AM	Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board (GlobeNewswire)
Aug-12-22 09:30AM	Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-22 03:00PM	Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST (GlobeNewswire)
Aug-04-22 09:30AM	Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 (GlobeNewswire)
Aug-03-22 04:00PM	Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 (GlobeNewswire)
Jul-12-22 08:30AM	Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022 (GlobeNewswire)
Jun-24-22 09:06AM	Here's Why We're Watching Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Situation (Simply Wall St.) +5.21%
May-12-22 04:20PM	Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.94%
May-05-22 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST (GlobeNewswire)
Apr-20-22 08:30AM	Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine) (GlobeNewswire)
Apr-05-22 08:30AM	Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis (GlobeNewswire)
Mar-30-22 04:00PM	Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update (GlobeNewswire)
Mar-23-22 08:30AM	Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST (GlobeNewswire)
Mar-10-22 08:30AM	Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-26-22 08:15AM	Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022 (GlobeNewswire)
Jan-17-22 08:42AM	Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Nov-11-21 04:05PM	Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:15AM	Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis (GlobeNewswire)
Oct-26-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST (GlobeNewswire)
Oct-19-21 10:22AM	What Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares? (Simply Wall St.) -6.74%
Oct-12-21 08:30AM	Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis (GlobeNewswire)
Sep-16-21 11:05AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update (GlobeNewswire) +5.52%
08:30AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-21 04:00PM	Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27 (GlobeNewswire) +5.89%
Aug-20-21 10:54AM	Companies Like Processa Pharmaceuticals (NASDAQ:PCSA) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-12-21 05:15PM	Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
Aug-06-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST (GlobeNewswire)
Aug-05-21 09:51AM	Buy These 3 Stocks Before They Double (or More), Say Analysts (TipRanks) +7.83%
Aug-04-21 08:30AM	Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer (GlobeNewswire)
Jul-27-21 08:30AM	Processa Pharmaceuticals to Present at Zooming with LD Micro Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET (GlobeNewswire) -6.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jul-06-21 08:15AM	Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET (GlobeNewswire)
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jun-17-21 09:15AM	PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117 (GlobeNewswire)
Jun-08-21 09:15AM	Processa Set to Join Russell Microcap® Index (GlobeNewswire)
Jun-07-21 04:05PM	Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET (GlobeNewswire)
May-26-21 09:15AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-21 04:05PM	Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica (GlobeNewswire) +5.54%
04:15AM	Read This Before Selling Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares (Simply Wall St.)
May-18-21 04:05PM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.11%
May-13-21 04:55PM	Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
May-07-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST (GlobeNewswire)
Mar-25-21 04:06PM	Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update (GlobeNewswire)
Mar-22-21 09:15AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET (GlobeNewswire)
Mar-17-21 09:15AM	Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica (GlobeNewswire)
Mar-02-21 09:15AM	Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement (GlobeNewswire)
Feb-22-21 08:30AM	Encode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc. (Newsfile) +6.80%
Feb-19-21 05:16AM	Do Institutions Own Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares? (Simply Wall St.)
Feb-17-21 08:00AM	Processa Pharmaceuticals Announces $10.2 Million Strategic Financing (GlobeNewswire) +33.17%
Jan-11-21 10:50AM	Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference (GlobeNewswire)
Nov-16-20 12:48PM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.39%
Nov-12-20 05:02PM	Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update (GlobeNewswire)

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young David	Pres. Research & Development	Feb 07 '24	Buy	2.45	21,000	51,526	79,387	Feb 08 04:30 PM
Young David	Pres. Research & Development	Feb 06 '24	Buy	2.53	20,000	50,504	58,387	Feb 07 04:22 PM
Lin Patrick	Chief Business - Strategy Off	Feb 01 '24	Buy	2.40	1,500	3,600	27,478	Feb 01 06:32 PM
Lin Patrick	Chief Business - Strategy Off	Jan 31 '24	Buy	2.37	2,500	5,925	25,978	Feb 01 06:32 PM
Ng George K	Chief Executive Officer	Jan 30 '24	Buy	2.70	10,000	27,000	20,000	Jan 31 04:37 PM
Yorke Justin W	Director	Jan 30 '24	Buy	2.69	8,000	21,544	31,232	Jan 31 04:34 PM
Young David	President & CEO	Jun 12 '23	Buy	0.80	40,000	32,000	470,424	Jun 12 04:31 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LGVN

Longeveron Inc

PCSA

Processa Pharmaceuticals Inc

Upgrade your FINVIZ experience